RADx® Tech and ATP Programs

The RADx® Tech/ATP programs are components of the overarching RADx Initiative at NIH to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The RADx Tech/ATP innovation funnel was designed to compress the customary technology development timeline from years down to just months.  This was accomplished by employing, in parallel, expert teams to address technical, regulatory, clinical, and commercialization requirements. Launched on April 29, 2020, the RADx programs were able to validate, de-risk, scale up, manufacture, and deploy novel tests through a seamless pipeline by fall 2020. 

In 2020 and 2021, these programs have increased testing capacity in the U.S. by hundreds of millions. As the COVID-19 pandemic evolves, NIBIB continues to support projects to fill unmet needs in diagnostic testing. 

generic bar chart titled tests produced

Program Dashboard

Summary data on proposals submitted to the RADx Tech and ATP Programs.

  • 960 million tests produced 
  • 100 companies supported
  • 35 FDA authorizations
colorful timeline arranged as steps toward a large arrow on the right

RADx Tech Timeline

See the milestones and success that have unfolded since the beginning of the RADx Tech program.

RADx Tech organization chart

Partners

The RADx Tech and ATP programs leverage the Point of Care Technology Research Network and joined with numerous other federal agencies, offices, NIH institutes, and contractors.

RADx Testing

Tests in Development

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

Learn more about this accelerated pathway designed to help bring to market over the counter diagnostic tests for COVID-19 that are not yet authorized by the FDA.

When to Test tool now has an individual calculator to help guide individuals and families on COVID-19 testing. The Testing Impact Calculator also includes tools to help organizations plan for and develop testing strategies, and playbooks for pooled testing and K-12 schools. This site includes other resources on testing strategies and obtaining supplies. Try the calculator.

The Say Yes COVID Test project is a cooperative effort from state and local health departments, NIH, and CDC.  This program offers access to free, rapid, at-home COVID-19 testing in select communities throughout the U.S. Learn more.  

Information about studies to evaluate diagnostic tests being developed for COVID-19.

This webinar series hosted by POCTRN provides information on RADx® Tech/ATP program activities.  Register for upcoming events or watch previous webinars.

Videos

View videos about RADx Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

Program Contacts

Current grantees contact Program Director on your existing award.

RADx® Tech programmatic or technical inquiries: info.radx@poctrn.org

All other RADx® Tech Applicants: RADxNIBIB@mail.nih.gov 

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov 

All others: COVID19Grants@nih.gov 

Related Resources

Related News

November 3, 2021
smart phone in person's hands
The NIH RADx initiative today announced the launch of the When To Test Calculator for Individuals, a companion to the version for organizations introduced last winter. By responding to just a few prompts, the new individual impact calculator indicates whether a person should get a test—now or soon.
October 25, 2021
hands holding COVID test
NIH is investing $70 million from the American Rescue Plan to help bring more high-quality, at-home tests onto the market in the U.S. in coordination with the FDA. NIH’s new Independent Test Assessment Program (ITAP) will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.
October 14, 2021
The National Institutes of Health's Rapid Acceleration of Diagnostics initiative announced on Thursday that it has awarded $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2. Source: Genomeweb
October 14, 2021
packaging and testing device
The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.
October 14, 2021
Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).